Clareo Health | Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Male or female participants aged 18 years and older with a documented diagnosis of primary ITP in the medical history
Participant received at least one course of first-line therapy and had a history of response while on treatment
Participant has loss of response, relapse, or steroid dependency
You may not be if
Participants with Secondary ITP
Participants with Evans syndrome or history of myelodysplastic syndrome
Participants with history of lymphoma, leukemia, or any malignancy within the past 5 years except for non-melanoma skin malignancy.
Participants with history of solid organ transplant
Participants with history of coagulation or bleeding disorders other than ITP, including genetic conditions, other than ITP
Participant received advanced therapy for ITP or was splenectomized
Pregnancy or nursing The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
